1. Introduction
===============

In recent years, the diagnostic rate of multiple primary malignant tumors (MPMNs) has increased due to the improvement of tumor diagnosis level and the prolongation of survival time of patients with malignant tumors. The prevalence of MPMTs in foreign studies ranged from 11.0% to 21.0%;^\[[@R1],[@R2]\]^ however, the prevalence of MPMTs was reported to be 0.99% in China.^\[[@R3]\]^ So second primary cancer (SPC) is still rare and difficult to distinguish from metastasis in clinic. Here, we present a case of papillary thyroid carcinoma (PTC) with lung metastasis and primary lung cancer.

2. Case presentation
====================

Previous written and informed consent were obtained from the patient, and this study was approved by the ethics review board of Soochow University. A 66-year-old man with history of semithyroidectomy 7 years ago for PTC presented a chest mass with pain for 1 month. The patient had significantly raised serum Tg of 500 ng/mL (reference range, 3.50--77.00 ng/mL) and abnormal tumor markers: CEA 85.02 (reference range, 0--5.00 ng/mL), CA19-9 97.41 U/mL (reference range, 0-37.00 U/mL), CA125 80.32 U/mL (reference range, 0--35.00 U/mL). The whole-body ^18^F-fluorodexyglucose positron emission tomography/computed tomography (^18^F-FDG PET/CT) presented several lesions (Fig. [1](#F1){ref-type="fig"}A), a nodule of right upper lobe with intense FDG uptake (SUVmax 7.6; Fig. [1](#F1){ref-type="fig"}B), nodules of inferior lobes with slight FDG uptake (SUVmax 1.6; Fig. [1](#F1){ref-type="fig"}C), enlarged supraclavicular and mediastinum lymph nodes with intense FDG uptake (SUVmax 11.4; Fig. [1](#F1){ref-type="fig"}D/F) and left 3rd costa damage with intense FDG uptake (SUVmax 8.1; Fig. [1](#F1){ref-type="fig"}E).

![Imaging findings on ^18^F-PET/CT. (A) The whole-body ^18^F-FDG PET/CT presented several lesions; (B) a nodule of right upper lobe with intense FDG uptake; (C) nodules of inferior lobes with slight FDG uptake; (D, F) enlarged supraclavicular and mediastinum lymph nodes with intense FDG uptake; (E) left 3rd costa damage with intense FDG uptake. ^18^F-FDG = ^18^F-fluorodexyglucose, PET/CT = positron emission tomography/computed tomography.](medi-96-e9078-g001){#F1}

The CT-guided biopsy for histopathological diagnosis of chest mass affirmed metastasis from thyroid (Fig. [2](#F2){ref-type="fig"}A). Thus, the patient received thyroidectomy and left cervical lymph node dissection. The thyroid operated confirmed to be multinodular goiter (Fig. [2](#F2){ref-type="fig"}C), while metastases have been found in cervical lymph nodes (Fig. [2](#F2){ref-type="fig"}B). The nodule of right upper lobe received CT-guided biopsy and was confirmed to be pulmonary adenocarcinoma, mucous adenocarcinoma partly (Fig. [2](#F2){ref-type="fig"}D).

![(A) Chest mass was affirmed metastasis from thyroid (HES ×100). (C) The thyroid operated confirmed to be multinodular goiter (HES ×200), while metastases have been found in cervical lymph nodes (B, HES ×200). (D) The nodule of right upper lobe was confirmed to be pulmonary adenocarcinoma, mucous adenocarcinoma partly (IH ×200). HES = hematoxylin, eosin, saffran, IH = immunohistochemistry.](medi-96-e9078-g002){#F2}

The patient received 2 times I-131 radioiodine therapy after surgery (150mCi, 200mCi; 6 months apart). Compared with first therapy, lesions of cervical lymph nodes, right humerus, and right ilium disappeared after the second therapy, while lesions of left 3rd costa and nodules of inferior lobes shrank (Before: Fig. [3](#F3){ref-type="fig"}A; After: Fig. [3](#F3){ref-type="fig"}B). The CT confirmed the shrink of the iodine avid nodules (Fig. [3](#F3){ref-type="fig"}C). Follow-up for 2 years, they almost disappeared in CT (Fig. [3](#F3){ref-type="fig"}D). The nodule of right upper lobe was non-iodine avid all the time. Follow-up by CT, diameter of this nodule increased 0.9 cm after 2 times I-131 radioiodine therapy (Fig. [3](#F3){ref-type="fig"}E). The nodule was histopathologically confirmed to be pulmonary adenocarcinoma. One year after I-125 seed brachytherapy and chemotherapy, the diameter shrank to only 0.7 cm (Fig. [3](#F3){ref-type="fig"}F).

![(A, B) The patient received 2 times I-131 radioiodine therapy after surgery. (C) The CT confirmed the shrink of the iodine avid nodules. (D) Follow-up for 2 years, they almost disappeared in CT. (E) Diameter of nodule in right upper lobe increased 0.9 cm after 2 times I-131 radioiodine therapy. (F) One year after I-125 seed brachytherapy and chemotherapy, the diameter shrank to only 0.7 cm. CT = computed tomography.](medi-96-e9078-g003){#F3}

3. Discussion
=============

A multicenter study of 377 MPMTs from Turkey found that the most frequent initial cancer types were head and neck (54 patients, 14.3%); the most frequent second cancer types were lung (76 patients, 20.2%); the most common cancer pairs in males were head and neck-lung cancers (29 patients, 13%).^\[[@R2]\]^ Liu et al^\[[@R3]\]^ found that MPMTs were observed more frequently in patients with head and neck tumors (5.65%) and was over 4-fold greater than the prevalence of MPMTs in all patients (0.99%). The ratio of top 3 in SPC was digestive system tumors, lung cancer, and leukemia/lymphoma, respectively.^\[[@R3]\]^ In addition to chemotherapy and radiotherapy, Liu believed that the higher survival time of patients with head-neck tumors may be a potential factor for suffering from MPMTs.^\[[@R3]\]^ The patient was an elderly male patient who had undergone PTC for 7 years. Therefore, doctors should pay attention to the development of SPC for suspicious pulmonary nodules.

Primary lung adenocarcinoma with pulmonary metastases of PTC at the same time was rarely reported,^\[[@R4],[@R5]\]^ and lack of detailed diagnosis, treatment, follow-up information. As reported, about half pulmonary metastases of PTC are non-iodine avid with worse prognosis.^\[[@R6]\]18^F-FDG PET/CT is recommended in high-risk aggressive differentiated thyroid cancer patients with elevated serum Tg.^\[[@R7],[@R8]\]^ While FDG avid and non-iodine avid is not sufficient to distinguish lung primary cancer from metastasis, elevated tumor markers should not be ignored in this situation. CEA, CA125, and CA19-9 can elevate in medullary thyroid cancer,^\[[@R9]\]^ but rarely observed in PTC. Once the diagnosis of SPC is clear, I-125 seed brachytherapy is a good method to improve the prognosis of patients with inoperable stage III/IV nonsmall cell lung cancer.^\[[@R10]\]^

In conclusion, clinicians should improve the understanding of SPC and improve the diagnostic accuracy by laboratory examination, imaging, and pathology. Moreover, reasonable treatment should be adopted to make the patients have better prognosis.
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